Skip to main content

Table 2 Proliferation. Effects of abciximab (0.0002, 0.002, 0.02, 0.2, 2.0, and 20.0 μg/ml) on proliferation of HUVEC, HCAEC, and HCMSMC in comparison to untreated controls at day six after seeding, C = control, (p < 0.05 = *; p < 0.01 = **; p < 0.001 = ***; paired Student's t-test)

From: Effects of abciximab on key pattern of human coronary restenosis in vitro: impact of the SI/MPL-ratio

Proliferation (%) HUVEC HCAEC HCMSMC
C 100 ± 0 100 ± 0 100 ± 0
0,0002 μg/ml Abciximab 96,41 ± 6,16 88,5 ± 7,2 100,18 ± 17,10
0,002 μg/ml Abciximab 93,77 ± 3,88 87,17 ± 9,02 91,86 ± 15,64
0,02 μg/ml Abciximab 90,19 ± 1,77 88,35 ± 3,04 90,85 ± 11,33
0,2 μg/ml Abciximab 90,37 ± 7,38 85,09 ± 8,27 86,90 ± 8,43
2 μg/ml Abciximab 83,47 ± 2,51 91,87 ± 3,25 85,79 ± 8,56
20 μg/ ml Abciximab 79,34 ± 9,16 87,70 ± 6,01 81,09 ± 7,59